| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000003222 |
| Receipt No. | R000003902 |
| Official scientific title of the study | Assessment of Neointimal Stent Strut Coverage and Endothelial Function After Second Generation Drug-Eluting Stent Systems |
| Date of disclosure of the study information | 2010/03/01 |
| Last modified on | 2018/12/01 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Assessment of Neointimal Stent Strut Coverage and Endothelial Function After Second Generation Drug-Eluting Stent Systems | |
| Title of the study (Brief title) | Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents (ASSESS) | |
| Region |
|
|
| Condition | ||
| Condition | Stable angina pectoris | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To compare coronary endothelium function in patients with a zotarolimus-eluting versus a sirolimus-eluting or a everolimus-eluting stents with optical coherence tomography, vasoconstrictioin in response to acetylcholine, and coronary biomarker level. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | 1. To compare coronary endothelial function after primary angioplasty
2. To compare the presence of neointimal stent strut coverage via optical coherence tomography 3. To compare the serum biomarker levels measured in coronary artery blood |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | |
| Blinding | Open -but assessor(s) are blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Zotarolimus-eluting stent | |
| Interventions/Control_2 | Sirolimus-eluting stent | |
| Interventions/Control_3 | Everolimus-eluring stent | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Significant coronary de novo lesion (70% by quantitative angiographic analysis)
2. Patients with stable angina pectoris considered for coronary intervention 3. Reference vessel diameter of 2.5 to 3.5 mm by operator assessment |
|||
| Key exclusion criteria | 1. Contraindication to anti-platelet agents
2. Ostial lesion within 5mm from ostium 3. Different DES in other vessel simultaneously 4. Creatinine level more than 2.5mg/dl 5. Left main stenosis more than 50% 6. Vein graft lesion 7. Triple vessel disease with stenosis more than 50% in 3 epicardial coronary arteries 8. Life expectancy 1 year 9. Reference vessel diameter <2.5mm or >4.0mm by visual 10. Long lesion that require more than three stents |
|||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Kenichi Fujii |
| Organization | Hyogo College of Medicine |
| Division name | Cardiovascular Division |
| Address | 1-1 Mukogawa-cho, Nishinomiya-city, Hyogo 6638501 JAPAN |
| TEL | |
| Public contact | |
| Name of contact person | Kenichi Fujii |
| Organization | Hyogo College of Medicine |
| Division name | Cardiovascular Division |
| Address | |
| TEL | 0798-45-6553 |
| Homepage URL | |
| Sponsor | |
| Institute | Cardiovascular Division, Hyogo College of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Hyogo College of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | YES |
| Study ID_1 | NCT01073111 |
| Org. issuing International ID_1 | ClinicalTrials.gov |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003902 |